Second Genome Announces Bayer Exercised Option Following Completion of Multi-Year Collaboration

BRISBANE, Calif., March 2, 2022 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, announced today it has completed its multi-year collaboration with Bayer to discover proteins for...

Click to view original post